BeOne Medicines (BEIGF) Change in Receivables (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Change in Receivables data on file, last reported at $75.3 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $75.3 million, up 136.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $208.4 million (down 25.92% YoY), and the FY2025 annual result was $165.0 million, down 49.93% from the prior year.
• Change in Receivables rose to $75.3 million in Q1 2026 per BEIGF's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Change in Receivables peaked at $136.5 million in Q1 2023 and troughed at -$292.6 million in Q1 2022.
• A 5-year average of $26.7 million and a median of $31.9 million in 2025 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables plunged 1336.7% in 2022, then jumped 2156.77% in 2024.
• A 5-year view of Change in Receivables shows it stood at -$19.4 million in 2022, then soared by 330.96% to $44.8 million in 2023, then soared by 180.61% to $125.7 million in 2024, then sank by 101.86% to -$2.3 million in 2025, then soared by 3317.95% to $75.3 million in 2026.
• Business Quant data shows BEIGF's Change in Receivables at $75.3 million in Q1 2026, -$2.3 million in Q4 2025, and $93.9 million in Q3 2025.